Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Date:9/11/2012

GIES, INC.and SubsidiaryConsolidated Balance Sheets(unaudited)June 30, 2012June 30, 2011ASSETSCurrent assets:Cash and cash equivalents

$
3,827,198$
8,869,639Accounts receivable

27,631131,149Restricted cash

350,000-Prepaid expenses and other current assets

532,010261,947Total current assets

4,736,83919,262,735Property and equipment, net

318,6531,305,331Restricted cash

-350,000Other assets

324,992254,787Total assets

$
5,380,484$
21,172,853LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Capital lease obligations

$
22,277$
34,923Accounts payable 

294,894496,908Accrued expenses

2,706,4961,854,007Accrued compensation

433,333374,094Unearned revenue

-46,105Total current liabilities

3,457,0002,806,037Capital lease obligations 

19,90942,186Deferred rent

72,677132,855Total liabilities

3,549,5862,981,078Stockholders' equity:Preferred stock of $0.01 par value – authorized 10,000,000 shares;Series A Convertible; issued and outstanding 4,997 shares as of June 30, 2012 and 2011, respectively

5050Common stock of $0.01 par value – authorized 100,000,000 shares; issued and outstanding 34,900,591 shares as of June 30, 2012 and 2011, respectively

349,006349,006Additional paid-in capital

240,725,127239,832,826Accumulated deficit 

(239,243,285)(221,990,107)Total stockholders' equity

1,830,89818,191,775Total liabilities and stockholders' equity

$
5,380,484$
21,172,853
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 30, 2014 In response to ... to address sales, training and consumer engagement challenges, ... innovative mobile applications to turn their clients’ visions ... latest customized mobile app creations, are now featured ... In partnership with Toyota, StudioPMG created a robust ...
(Date:10/1/2014)... The U.S. Department of Labor has ... Edwardsville as part of the Trade Adjustment Assistance Community ... co-administered by the Department of Labor and Department of ... Thomas E. Perez and Secretary of Education Arne Duncan ... grants to nearly 270 colleges across the country. ...
(Date:9/30/2014)... available in German . ... Mnchen (TUM) have demonstrated a new kind of building ... future computer chips could be based on three-dimensional arrangements ... enabling technology of the semiconductor industry CMOS fabrication ... researchers and collaborators at the University of Notre Dame ...
(Date:9/30/2014)... Sept. 30, 2014 Nematicide is a ... Nematodes are microscopic parasitic roundworms, found in massive ... other plants and animals. Nematicides have tended to ... properties promoting migration through the soil. A single ... plant-parasitic nematodes. With more than 10,000 species classified, ...
Breaking Biology Technology:Digital Agency Studio PMG Launches New Case Studies on Website 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 2U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 3U.S. Dept. of Labor Awards SIUE Nearly $10-Million Grant 4A new dimension for integrated circuits: 3-D nanomagnetic logic 2A new dimension for integrated circuits: 3-D nanomagnetic logic 3Nematicides Market by Types (Fumigants, Organophosphates, Carbamate and Bio-Nematicides), Applications (Agrochemicals, Industrial, and Others), and Geography (North America, Europe, Asia-Pacific & ROW) - Global Trends & Forecasts to 2019 2
... Calif. and MONROVIA, Calif., Jan. 6, 2011 Amgen ... today that they will collaborate to develop XmAb ® ... and CD32b.  XmAb5871 is currently in late-stage preclinical development ... Under the terms of the agreement, Amgen has the ...
... SAN FRANCISCO, Jan. 6, 2011 Vista Partners ... Therapeutics, Inc. (Nasdaq: OPXA ) and raised ... Silver, Principal Analyst at Vista Partners stated, "Opexa announced yesterday ... for the treatment of Multiple sclerosis , is now ...
... 6, 2011 BioInformatics, LLC announces the release of ... Technologies:  Market Insights for Life Science Suppliers (#10-005) This ... respond in a timely fashion to the rapidly changing ... LLC quantifies and characterizes the market for genetic analysis ...
Cached Biology Technology:Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases 2Amgen and Xencor Enter Option Deal to Co-Develop Xencor's Novel Antibody for Autoimmune Diseases 3Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Raises Target Price From $4.40 to $6.50 2BioInformatics, LLC New Market Report - Genomics Technologies 2
(Date:9/30/2014)... know what goes wrong with your muscles because of age, ... "normal" actually is. That,s where a new research report published ... Journal comes in. In the report, a team ... that can help scientists "see" which genes are active in ... never-before-detected gene activity and that men have approximately 400 more ...
(Date:9/30/2014)... release is available in German . ... their behavioural response to risky situations such as exposure ... Ornithology now found in a long-term study on different ... both metabolic rate and ambient temperature. High metabolic rates ... as in these scenarios birds were more likely to ...
(Date:9/30/2014)... a suite of perilous threats in today,s ocean. ... climate change, fragile coral ecosystems are disappearing at ... some species of corals surrounding the island of ... in their tropical environment: coral guard-crabs. New research ... Marine Station scientist Seabird McKeon and the museum,s ...
Breaking Biology News(10 mins):Scientists identify which genes are active in muscles of men and women 2Risky metabolism 2Smithsonian scientists discover coral's best defender against an army of sea stars 2
... , Jan. 24, 2013 /PRNewswire-iReach/ -- The companion diagnostics ... has become one of the most promising areas within ... companies are now entering the highly attractive market of ... developing a combination product. The explosive M&A trend in ...
... their mother,s diet during gestation and lactation were found to ... than those not exposed to the chemical, researchers at the ... BPA is a chemical most commonly found in the lining ... in many hard plastic bottles, including baby bottles, but many ...
... Researchers at the University of Pittsburgh School of ... key HIV protein. In findings published online today in ... this vulnerable spot could stop the virus from replicating, ... Previous research demonstrated that a small HIV protein ...
Cached Biology News:Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player 2Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player 3Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player 4Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player 5Female mice exposed to BPA by mothers show unexpected characteristics 2Female mice exposed to BPA by mothers show unexpected characteristics 3Pitt team finds 'Achilles Heel' of key HIV replication protein 2
Mouse monoclonal antibody to ALAS2 - aminolevulinate, delta-, synthase 2 (sideroblastic/hypochromic anemia)...
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
Mouse monoclonal antibody raised against a partial recombinant FBXO24. NCBI Entrez Gene ID = FBXO24...
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
Biology Products: